Orion Corp
KRX:271560

Watchlist Manager
Orion Corp Logo
Orion Corp
KRX:271560
Watchlist
Price: 104 800 KRW -0.47% Market Closed
Market Cap: 4.1T KRW
Have any thoughts about
Orion Corp?
Write Note

Net Margin
Orion Corp

12.7%
Current
12%
Average
3.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.7%
=
Net Income
383.5B
/
Revenue
3T

Net Margin Across Competitors

Country KR
Market Cap 4.1T KRW
Net Margin
13%
Country JP
Market Cap 53.2T JPY
Net Margin
4%
Country CH
Market Cap 190.5B CHF
Net Margin
12%
Country US
Market Cap 80.1B USD
Net Margin
11%
Country ZA
Market Cap 45.5B Zac
Net Margin
8%
Country FR
Market Cap 41.2B EUR
Net Margin
4%
Country MY
Market Cap 169.8B MYR
Net Margin
4%
Country US
Market Cap 37B USD
Net Margin
5%
Country ZA
Market Cap 35.9B Zac
Net Margin
14%
Country CN
Market Cap 257.7B CNY
Net Margin
23%
Country US
Market Cap 35.2B USD
Net Margin
13%
No Stocks Found

Orion Corp
Glance View

Market Cap
4.1T KRW
Industry
Food Products

Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.

Intrinsic Value
155 742.72 KRW
Undervaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.7%
=
Net Income
383.5B
/
Revenue
3T
What is the Net Margin of Orion Corp?

Based on Orion Corp's most recent financial statements, the company has Net Margin of 12.7%.